STOCK TITAN

Heartbeam, Inc. - BEAT STOCK NEWS

Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.

HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.

HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.

Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.

One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.

HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.

Latest News: Source: HeartBeam, Inc.

  • ------
  • ------
  • ------
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar scheduled for April 27, 2022, at 11:30 a.m. Eastern Time. The event will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt discussing recent company announcements and key milestones for 2022. Participants can join via a provided webcast link or dial-in numbers. A replay will be available for two months post-event. HeartBeam focuses on innovative ECG telemedicine technology aimed at enhancing heart attack detection for high-risk patients outside medical facilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.93%
Tags
conferences
-
Rhea-AI Summary

HeartBeam, a digital healthcare company focused on ECG telemedicine for heart attack detection, announced significant progress for Q4 2021, including partnerships for its Emergency Department (ED) myocardial infarction software and telehealth solutions. Key highlights include a $14.9 million IPO, new partnerships with LIVMOR Inc. and Phoebe Putney Health System, and an experienced leadership team poised for commercialization. The company ended 2021 with $13.2 million in cash, projecting sufficient funds into 2023, aiming for FDA submissions in 2022 and 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has entered a professional services agreement with Triple Ring Technologies for the development of a Telehealth 3D vector ECG collection device aimed at remote heart attack monitoring. This partnership will span five phases and is scheduled for FDA 510k submission in Q4 2022. The device is designed for patient use at home, providing crucial ECG data to physicians in real-time. With over 18 million people in the U.S. suffering from coronary artery disease, this innovative solution addresses a significant need in cardiac care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
partnership
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) will conduct a conference call on March 24, 2022, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year results for fiscal 2021, ending December 31, 2021. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. A press release with results will precede the call. Interested parties can join via phone or webcast. A telephone replay will be available until June 24, 2022. HeartBeam focuses on innovative ECG technology for heart attack detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
conferences
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has announced a Business Associate Agreement and Clinical Trial Agreement with Phoebe Putney Health System to conduct a pilot study of HeartBeam’s Myocardial Infarction software product. This partnership aims to evaluate the software’s effectiveness in detecting heart attacks in emergency settings. HeartBeam will conduct additional studies and pursue future scientific and commercial collaborations, enhancing its position in the telehealth space for remote heart attack detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
partnership
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has announced a partnership with LIVMOR Inc. to develop a HeartBeam branded version of LIVMOR's FDA-cleared Halo+ Remote Patient Monitoring (RPM) platform. This collaboration aims to enhance heart attack detection by customizing the platform for HeartBeam's products. CEO Branislav Vajdic emphasized that using LIVMOR's established platform will expedite the FDA submission of their heart attack detection software, aimed at Emergency Department settings, later this year. This partnership aims to improve the accuracy of myocardial infarction detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
partnership
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has established a Scientific Advisory Board (SAB) to enhance its medical studies and product development. The board will be chaired by C. Michael Gibson, an esteemed cardiologist known for his work in cardiovascular research. Dr. Gibson's extensive experience includes leading over 120 clinical trials and contributing to major cardiac drug approvals. This strategic move aims to bolster HeartBeam's proprietary ECG telemedicine technology, focusing on accurate heart attack diagnosis in ambulatory settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
management
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT), a digital healthcare company, announced its participation in the H.C. Wainwright BIOCONNECT Conference from January 10-13, 2022. Key executives, including CEO Branislav Vajdic, will conduct video meetings during the event. The conference aims to showcase HeartBeam's innovative ECG telemedicine technology, designed to diagnose cardiovascular diseases effectively outside traditional medical settings. This breakthrough technology targets a significant market need, particularly in diagnosing heart attacks in high-risk patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences
-
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has appointed Alan Baumel as the new Chief Operating Officer, a role focused on product development and regulatory affairs for their innovative ECG telemedicine technology. With over 35 years in the medical device sector, Baumel is expected to enhance HeartBeam's commercialization strategy and accelerate FDA product development. His experience includes leadership roles at Bardy Diagnostics and contributions to improving medical device quality and safety. HeartBeam aims to address significant needs in heart attack detection outside medical institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
management
Rhea-AI Summary

HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed a $16.5 million IPO, selling 2,750,000 units at $6.00 each. The IPO generated net proceeds of $14.9 million, boosting the company’s cash balance to approximately $15.7 million. HeartBeam aims to advance its FDA-ready telemedicine solutions for cardiovascular assessment, with significant milestones set for 2022 and 2023. Q3 2021 financial results show an increased net loss of $1.2 million, up from $335,000 in Q3 2020, while R&D expenses rose to $105,000 from $57,000 year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.94%
Tags

FAQ

What is the current stock price of Heartbeam (BEAT)?

The current stock price of Heartbeam (BEAT) is $2.39 as of December 24, 2024.

What is the market cap of Heartbeam (BEAT)?

The market cap of Heartbeam (BEAT) is approximately 63.7M.

What does HeartBeam, Inc. do?

HeartBeam, Inc. develops high-resolution ambulatory ECG solutions for detecting and monitoring cardiac disease outside traditional healthcare settings.

What is unique about HeartBeam's technology?

HeartBeam's technology includes a credit card-sized ECG device and a cloud-based diagnostic system that performs as well as top cardiologists in diagnosing heart attacks.

How does HeartBeam's iCardiologist application work?

The iCardiologist application uses AI and machine learning to continuously improve its diagnostic accuracy and predictive capabilities, assisting cardiologists in patient analysis.

What is VECG technology?

VECG stands for Vector Electrocardiography, a proprietary and patented platform developed by HeartBeam to provide higher-resolution ECG solutions.

Has HeartBeam's technology been validated?

Yes, studies by Harvard Medical School faculty have shown that HeartBeam's performance is equal to or better than world-class cardiologists in diagnosing heart attacks.

Is HeartBeam seeking FDA clearance?

Yes, HeartBeam is currently seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.

What are the benefits of HeartBeam's ECG solutions?

HeartBeam's solutions offer accessible, high-resolution cardiac monitoring useful outside of traditional healthcare settings, providing early detection and monitoring of cardiac conditions.

Can HeartBeam's technology locate a heart attack?

Yes, the technology can help cardiologists locate a heart attack on a 3D model of the heart using personalized diagnostic thresholds and novel ECG markers.

How is HeartBeam improving cardiac care?

HeartBeam is improving cardiac care by developing practical, high-resolution ECG solutions that provide critical diagnostic tools accessible outside traditional healthcare environments.

Where can I find the latest news on HeartBeam, Inc.?

The latest news and updates on HeartBeam, Inc. can be found on StockTitan and other financial news platforms.

Heartbeam, Inc.

Nasdaq:BEAT

BEAT Rankings

BEAT Stock Data

63.73M
18.98M
29.25%
8.73%
0.47%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States of America
SANTA CLARA